The potential for using the body's own defense mechanisms against cancer was suggested many years ago when Burnet proposed the concept of immune surveillance (2) . The concept states that the immune system can recognize and destroy transformed cells progressing toward malignancy, as well as fully transformed malignant neoplasms. Early attempts to induce a significant tumor response in patients were plagued with failures, due at least partly to large tumor burdens and insufficient knowledge of the complex interactions that occur between tumor cells and cells of the immune system. Although the existence of significant immunological defense against cancer has been controversial, it is now clear that cells of the immune system are capable of waging a lethal attack against tumor targets. The lack of tumor control has been increasingly linked to escape mechanisms that are either host-or tumor-derived. These escape mechanisms include deficiency in tumor antigen processing and presentation, limited access of effectors to the tumor site, signaling defects in T lymphocytes, downregulation of major histocompatibility complex (MHC) class I expression, lack of immunogenic tumor epitopes, and secretion of immunosuppressive cytokines such as transforming growth factor-β (TGF-β) and interleukin-10 (IL-10).
Numerous approaches are currently being explored in efforts to induce and/or enhance defensive immune responses, alone and in concert with already well established treatment regimens. In this issue, Dr. Muller and Dr. Pawelec review the status of cytokines as tools for upregulating antitumor immunity, as well as their potential for inducing anergy and thus facilitating tumor cell escape. Selective destruction of tumor vasculature by the administration of free and liposome-encapsulated tumor necrosis factor-α (TNF-α), a major cytokine produced by activated macrophages, is discussed by Dr. ten Hagen and Dr. Eggermont. Dr. Bex and his colleagues discuss results obtained from clinical trials of metastatic renal cell carcinoma, the controversy surrounding the timing of interferon alfa-2b immunotherapy and nephrectomy, and data from their own pilot study using interferon alfa-2b, granulocyte/macrophage -colony stimulating factor (GM-CSF), and IL-2. Dr. Kettering and his colleagues describe their data using an innovative com-Daila S. Gridley, Ph.D.
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Loma Linda, CA 92354, USA bination approach consisting of IL-2 gene therapy together with antisense TGF-β1 in a herpes-transformed tumor model. Dr. Timiryasova, Dr. Fodor, and colleagues describe their results following radiation and vaccinia-p53 gene therapy and the ensuing immunomodulation in an animal model of brain tumor. The rapidly evolving area of active immunization as a form of cancer therapy, with emphasis on allogeneic bone marrow transplantation after nonmyeloablative conditioning, is reviewed by Dr. Zöller. Although many questions still remain to be answered and many challenges lie ahead, these reports and the numerous other recent publications describing advances in cancer immunotherapy indicate that significant breakthroughs are sure to come in the near future.
